|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0013687,
umls-concept:C0017262,
umls-concept:C0029925,
umls-concept:C0162638,
umls-concept:C0185117,
umls-concept:C0205210,
umls-concept:C0220825,
umls-concept:C0301704,
umls-concept:C0549193,
umls-concept:C0699040,
umls-concept:C1510438,
umls-concept:C1707455,
umls-concept:C2347946,
umls-concept:C2911684
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2009-10-22
|
|
pubmed:abstractText |
Phosphatidylserine cell surface exposure during apoptosis can be detected by its binding to the protein annexin-V. We investigated annexin-V expression in 76 ovarian carcinoma effusions using flow cytometry. Results were analyzed for association with clinicopathologic parameters and survival. Annexin-V expression was additionally compared with the previously studied apoptotic markers cleaved caspase-3, cleaved caspase-8, and deoxyuridine triphosphate (dUTP) incorporation into DNA fragments. Annexin-V was expressed in all specimens and was more frequently detected compared with cleaved caspases and dUTP incorporation (P < .001). Annexin-V expression was higher in grade 3 vs grades 1 and 2 tumors (P = .014). A higher percentage of annexin-V-expressing cells in postchemotherapy specimens was associated with poor overall (P = .005) and progression-free (P = .013) survival. We present the first evidence of annexin-V expression in ovarian carcinoma effusions. The higher annexin-V expression compared with other apoptosis parameters and its association with high-grade disease and poor survival in postchemotherapy patients suggest a role in cell survival rather than apoptosis in effusions.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1943-7722
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
132
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
756-62
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:19846818-Adult,
pubmed-meshheading:19846818-Aged,
pubmed-meshheading:19846818-Aged, 80 and over,
pubmed-meshheading:19846818-Annexin A5,
pubmed-meshheading:19846818-Apoptosis,
pubmed-meshheading:19846818-Ascitic Fluid,
pubmed-meshheading:19846818-Caspase 1,
pubmed-meshheading:19846818-Caspase 3,
pubmed-meshheading:19846818-Cell Membrane,
pubmed-meshheading:19846818-Female,
pubmed-meshheading:19846818-Flow Cytometry,
pubmed-meshheading:19846818-Humans,
pubmed-meshheading:19846818-Immunophenotyping,
pubmed-meshheading:19846818-Kaplan-Meier Estimate,
pubmed-meshheading:19846818-Middle Aged,
pubmed-meshheading:19846818-Neoplasm Staging,
pubmed-meshheading:19846818-Ovarian Neoplasms,
pubmed-meshheading:19846818-Phosphatidylserines,
pubmed-meshheading:19846818-Pleural Effusion, Malignant,
pubmed-meshheading:19846818-Prognosis,
pubmed-meshheading:19846818-Tumor Markers, Biological
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Evaluation of cell surface expression of phosphatidylserine in ovarian carcinoma effusions using the annexin-V/7-AAD assay: clinical relevance and comparison with other apoptosis parameters.
|
|
pubmed:affiliation |
Division of Pathology, Norwegian Radium Hospital, Rikshospitalet University Hospital, Montebello N-0310 Oslo, Norway.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study
|
